Weekly issue 2026-W39 ·
From phenotypic screening to target and compound prioritization for autosomal dominant polycystic kidney disease
Plain language
Scientists tested thousands of compounds on lab-grown mini cysts made from kidney cells, then used computer tools to work out which body targets the active compounds hit. Blocking a sugar transporter (GLUT1) and switching on an adenosine receptor (A1) reduced cyst swelling, and one existing blood-pressure drug, esaxerenone, also did. This is early lab work that points to new research leads, not new treatments.
Clinical note
Phenotypic screen in 3D mIMCD3 Pkd1−/− forskolin-driven cyst-swelling assay, cross-referenced to Papyrus bioactivity data and prioritised by expression and non-antineoplastic profile. GLUT1 inhibitors reduced swelling; P2RX7 modulation had no effect; A1AR agonists reduced and the inverse agonist DPCPX increased swelling, with the positive allosteric modulator MIPS521 strongest; among MR antagonists only esaxerenone was active. QSAR analogues and radioligand binding supported an A1AR-linked hypothesis. Single cell-line model — requires mechanistic and in vivo confirmation.
Question for your next visit
How long does it usually take for a lab finding like this to reach a clinical trial, and are there trials I could follow?